HERSIMA 440MG ING

About

HERSIMA 440 MG INJECTION VIAL is a targeted therapy, specifically a monoclonal antibody, designed to bind to the human epidermal growth factor receptor 2 (HER2) protein. HER2 is a protein found on the surface of some cancer cells, and its overexpression can lead to aggressive tumor growth. By selectively binding to HER2, HERSIMA inhibits the growth and proliferation of HER2-positive cancer cells, making it a crucial treatment in certain types of breast and gastric cancers.

The mechanism of action involves several pathways, including inhibition of HER2 signaling, induction of antibody-dependent cell-mediated cytotoxicity (ADCC), and prevention of HER2 cleavage. This targeted approach allows for more specific action against cancer cells while minimizing damage to healthy cells compared to traditional chemotherapy. It is administered intravenously, often in combination with chemotherapy or other anti-cancer agents, and its use is guided by HER2 testing to ensure patient eligibility.

Uses

• Treatment of HER2-positive early breast cancer.
• Management of HER2-positive metastatic breast cancer.
• Therapy for HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma.
• Used in combination with chemotherapy.

Directions For Use

Administer intravenously under the supervision of a healthcare professional. Dosage and infusion rate are determined by patient weight, condition, and treatment protocol.

Benefits

• Targets specific HER2-positive cancer cells.
• Improves survival rates in HER2-positive cancers.
• Can reduce tumor recurrence.
• Effective in both early and metastatic disease.
• Often used in combination to enhance efficacy.
• Offers a personalized treatment approach.

Side Effects

• Cardiotoxicity (heart problems)
• Infusion-related reactions
• Diarrhea
• Nausea
• Fatigue
• Headache
• Rash
• Fever
• Chills
• Abdominal pain
• Anemia
• Neutropenia

Safety Measures

• Alcohol - No specific contraindication, but alcohol consumption should be discussed with a doctor, especially if experiencing side effects like fatigue or nausea.
• Pregnancy - Contraindicated during pregnancy due to potential fetal harm, including oligohydramnios and fetal renal impairment.
• Breastfeeding - Discontinue breastfeeding during treatment and for a period after the last dose due to potential harm to the infant.
• Liver - Use with caution in patients with pre-existing liver impairment; monitor liver function tests regularly.
• Kidney - Use with caution in patients with severe renal impairment; monitor renal function closely.
• Lung - Monitor closely for new or worsening pulmonary symptoms, as interstitial pneumonitis and other lung toxicities can occur.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.